ABSTRACT
Biomarkers are needed for personalized cancer therapy including early detection o f cancer, disease stratification and monitoring therapeutic outcomes. Recent advances in phosphoprotein enrichment and mass spectrometry (MS) technologies for quantitative phosphoproteome analysis in both global and targeted approaches provide great opportunities in the identification and validation o f phosphoprotein biomarkers. These technologies are useful tools for the identification o f phosphosignatures unique to a specific type or subtype o f cancer and drug responsive biomarkers for efficacy and toxicity. This chapter describes some examples o f phosphoproteins serving as cancer biomarkers, the advances ofphosphoprotein/phosphopeptide enrichment, MS technologies for global and targeted quantitative phosphoproteome analysis, biomarker validation and qualification and some interesting applications.
